Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitisinone
Therapeutic Area : Genetic Disease
Study Phase : Approved
Recipient : Analog Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Orfadin (nitisinone) is a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1.
Brand Name : Orfadin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2023
Lead Product(s) : Nitisinone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Analog Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
